Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP1 | P53582 | 1/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 4/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | CTSS | P25774 | 3/20 | 0.35 |
| ▸ | CTSK | P43235 | 3/20 | 0.35 |
| ▸ | CTSL | P07711 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
| ▸ | CTSA | P10619 | 1/20 | 0.33 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.33 |
| ▸ | ATR | Q13535 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7466599 | 0.85 | ABCB1 (0.50) | METAP1ABCB1TRPA1CNR2PPARG | |
| SCHEMBL8220279 | 0.81 | METAP1 (0.43) | METAP1ABCB1TRPA1CTSSCTSK | |
| SCHEMBL3055857 | 0.80 | ALOX12 (0.45) | METAP1ABCB1TRPA1TSHRHSD17B10 | |
| SCHEMBL15676168 | 0.79 | METAP1 (0.40) | METAP1ABCB1TRPA1CTSSCTSK | |
| SCHEMBL9593998 | 0.79 | METAP1 (0.42) | METAP1ABCB1TRPA1CTSSCTSK | |
| SCHEMBL4181986 | 0.79 | TRPA1 (0.39) | TRPA1CTSSCTSKCTSLPPARG | |
| SCHEMBL6441702 | 0.76 | CTSK (0.46) | CTSSCTSKCTSLPPARGPPARA | |
| SCHEMBL6577311 | 0.76 | CA1 (0.40) | METAP1ABCB1CTSSCTSKCTSL | |
| SCHEMBL4181570 | 0.75 | TSHR (0.39) | TRPA1CTSSCTSKATRTSHR | |
| SCHEMBL4179051 | 0.74 | PPARA (0.40) | TRPA1CTSSCTSKCTSLPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090186868-A1 | Taxane Compound Having Azetidine Ring Structure | DAIICHI SANKYO COMPANY LIMITED (JP) | 2009-07-23 | — | — | US | disclosed |
| EP-1942109-A1 | TAXANE COMPOUND WITH AZETIDINE RING STRUCTURE | Daiichi Sankyo Company, Limited (JP) | 2008-07-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186868-A1 | Taxane Compound Having Azetidine Ring Structure | ABCC1, AZI2, TPD52L2 | METAP1 4550/4885ABCB1 48/4885TRPA1 3951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.